Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 54

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 54
---
, 2024   |     | Annual    |     |               | — |     |        | 51,200 |
| Amar Murugan            |     | January 8, 2024   |     | Annual    |     |               | — |     |        | 19,000 |

(1) Amounts reflected in this column for RSUs granted in January 2024 have been adjusted to reflect the reverse stock split that occurred on June 20, 2024.

<div align='center'>34</div>

RSUs RSUs are viewed as an important retention vehicle for named executive officers, as well as a variable and at-risk component of executive compensation. Market trends reflect their favored use among our peer group and other companies in the biotechnology sector. The RSU awards granted in January 2024 vest quarterly and will generally be fully vested three years after the RSU grant date, subject to continuous service. In connection with his promotion to President and Chief Executive Officer, Dr. Nguyen was also granted RSUs with respect to 45,000 shares in September 2024, which will vest in twelve equal quarterly installments, subject to his continued service through each applicable vesting date. Other Compensation Policies and Practices Insider Trading Policy (including Anti-Hedging and Anti-Pledging) Our Insider Trading Policy prohibits all employees (including executive officers) and directors from: (i) buying or selling our stock while aware of any material nonpublic information; (ii) buying or selling our stock while our trading window is closed; and (iii) engaging in short sales, transactions in put or call options, hedging transactions, margin accounts, pledges or other inherently speculative transactions with respect to our stock at any time. Stock Ownership Guidelines Effective as of January 1, 2021, in order to further align their financial interests with those of our stockholders as well as to promote sound corporate governance, we adopted stock ownership guidelines for our named executive officers. These guidelines establish the following ownership targets for the value of stock held by each individual:

| Role                    |     | Ownership Guideline         
 (as a multiple of base pay) |
| Chief Executive Officer |     | 3x                          |
| All other Officers      |     | 1x                          |
| Non-employee Directors  |     | 3x                          |

The guidelines must be achieved (i) by each individual covered under the guidelines (a “Covered Individual”) by December 31, 2025 and (ii) for any